| Drug Name |
Terazosin |
| Drug ID |
BADD_D02158 |
| Description |
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837]. |
| Indications and Usage |
Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label]. |
| Marketing Status |
approved |
| ATC Code |
G04CA03 |
| DrugBank ID |
DB01162
|
| KEGG ID |
D08569
|
| MeSH ID |
C041226
|
| PubChem ID |
5401
|
| TTD Drug ID |
D0P9RF
|
| NDC Product Code |
51655-915; 68788-8171; 70518-3211; 70518-3193; 23155-738; 67296-1264; 23155-736; 62135-460; 70518-3272; 62135-459; 23155-735; 23155-737; 71335-9607; 60760-816; 62135-458; 62135-461 |
| UNII |
8L5014XET7
|
| Synonyms |
Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin |
